NDB Holding Group supports clients in navigating regulatory complexity, competitive pricing pressures, and evolving payer and provider dynamics while positioning for sustainable growth. This includes addressing portfolio strategy, manufacturing efficiency, regulatory compliance, market entry, and global commercialization.

Our Generics & Biosimilars Practice works with multinational manufacturers, regional players, and niche product companies worldwide. With a global presence, we help clients benchmark performance, analyze market opportunities, and identify growth prospects in both mature and emerging healthcare markets.

We advise clients on strategy, operations, regulatory affairs, and commercialization. Many of our consultants have backgrounds in pharmaceutical manufacturing, regulatory sciences, and healthcare markets, giving them deep insight into portfolio management, market access, and patient-focused delivery.

Our areas of expertise include:

• Portfolio strategy and lifecycle management: Optimizing product pipelines, evaluating launch timing, and prioritizing high-value opportunities.

• Manufacturing and operational efficiency: Enhancing production capacity, reducing cost of goods, and improving quality compliance across facilities.

• Regulatory and compliance strategy: Navigating global regulatory pathways, accelerating approvals, and managing biosimilar interchangeability and substitution.

• Market access and commercialization: Developing pricing, reimbursement, and launch strategies to maximize market penetration and revenue.

• Global expansion and partnerships: Identifying new market opportunities, forging alliances, and leveraging licensing or co-marketing arrangements.

Recent example of our work:
We assisted a leading biosimilars manufacturer in optimizing its global product portfolio and go-to-market strategy. By streamlining regulatory submissions, enhancing production efficiency, and targeting high-value markets, the client increased revenue potential by 25% and accelerated time-to-market for three key biosimilars.